Σύγκριση μεθόδων
Εξετάστε τις επιλεγμένες μεθόδους δίπλα-δίπλα· οι γραμμές που διαφέρουν επισημαίνονται.
| Συντελεστής Ομοιότητας Διάλυσης f1/f2× | Φαρμακομεταφορείς λιποσωμάτων× | |
|---|---|---|
| Πεδίο | Φαρμακολογία | Φαρμακολογία |
| Οικογένεια | Process / pipeline | Process / pipeline |
| Έτος προέλευσης≠ | 1996 | 1965 |
| Δημιουργός≠ | James Moore and Hector Flanner | Alec Bangham |
| Τύπος≠ | similarity testing | formulation technology |
| Θεμελιώδης πηγή≠ | Moore, J. W., & Flanner, H. H. (1996). Mathematical comparison of dissolution profiles. Pharmaceutical Technology, 20(6), 64-74. link ↗ | Bangham, A. D., Standish, M. M., & Watkins, J. C. (1965). Diffusion of univalent ions across the lamellae of swollen phospholipid films and the determination of membrane potential. Journal of Molecular Biology, 13(1), 238-252. DOI ↗ |
| Εναλλακτικές ονομασίες | f1, f2, similarity factor | liposomal formulation, vesicular delivery, lipid nanoparticles |
| Συναφείς | 3 | 3 |
| Σύνοψη≠ | The f1 and f2 factors are dimensionless statistical measures developed by Moore and Flanner to quantify the similarity between two dissolution profiles. Adopted by regulatory agencies (FDA, EMA) as the gold standard for comparing dissolution curves, these factors enable rapid assessment of whether formulation changes significantly impact drug release. | Liposomal encapsulation is a formulation technique using lipid bilayer vesicles (liposomes) to enclose drugs, improving bioavailability, reducing toxicity, and enabling targeted delivery. Developed by Alec Bangham in 1965, liposomes are now standard in pharmaceutical development, with several FDA-approved liposomal drugs on the market. |
| ScholarGateΣύνολο δεδομένων ↗ |
|
|